iifl-logo

Parmax Pharma Ltd Share Price

46
(-1.77%)
May 9, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open48
  • Day's High48
  • 52 Wk High55.02
  • Prev. Close46.83
  • Day's Low46
  • 52 Wk Low 25.03
  • Turnover (lac)0.45
  • P/E0
  • Face Value10
  • Book Value-2.16
  • EPS0
  • Mkt. Cap (Cr.)17.21
  • Div. Yield0
View All Historical Data
No Records Found

Parmax Pharma Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

48

Prev. Close

46.83

Turnover(Lac.)

0.45

Day's High

48

Day's Low

46

52 Week's High

55.02

52 Week's Low

25.03

Book Value

-2.16

Face Value

10

Mkt Cap (₹ Cr.)

17.21

P/E

0

EPS

0

Divi. Yield

0

Parmax Pharma Ltd Corporate Action

17 Sep 2024

12:00 AM

AGM

Announcement Date: 17 Sep, 2024

arrow

6 Feb 2025

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

17 Sep 2024

12:00 AM

BookCloser

arrow

Parmax Pharma Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Parmax Pharma Ltd SHAREHOLDING SNAPSHOT

09 May, 2025|06:53 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 30.80%

Foreign: 0.00%

Indian: 30.80%

Non-Promoter- 69.19%

Institutions: 0.00%

Non-Institutions: 69.19%

Custodian: 0.00%

Share Price

Parmax Pharma Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

4.45

4.45

4.45

4.45

Preference Capital

0

0

0

0

Reserves

-4.38

1.4

1.51

1.37

Net Worth

0.07

5.85

5.96

5.82

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2020Mar-2018Mar-2017Mar-2016

Revenue

20.91

11.9

0

0

yoy growth (%)

75.77

0

0

Raw materials

-11.26

-5.78

0

0

As % of sales

53.85

48.57

0

0

Employee costs

-2.91

-2.13

-0.01

0

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2020Mar-2018Mar-2017Mar-2016

Profit before tax

0.73

0

0

0.01

Depreciation

-1

-1.09

0

0

Tax paid

-0.3

0

-0.01

-0.01

Working capital

-0.24

-2.57

0.01

Other operating items

View Cash Flow
Y/e 31 MarMar-2020Mar-2018Mar-2017Mar-2016

Growth matrix (%)

Revenue growth

75.77

0

0

Op profit growth

63.49

-2,069.75

12.91

EBIT growth

2,335.31

587.94

-55.19

Net profit growth

78,904.6

-106.88

108.03

View Ratios

No Record Found

Parmax Pharma Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,766.2

134.524,23,770.541,181.050.765,985.3398.33

Divis Laboratories Ltd

DIVISLAB

5,958.35

76.31,58,175.475940.52,297513.62

Cipla Ltd

CIPLA

1,486.75

25.81,20,075.941,438.150.874,134.87360.72

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,183

59.051,07,722.354850.882,330222.38

Mankind Pharma Ltd

MANKIND

2,434.1

51.931,00,425.74416.3802,396.57334.17

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Parmax Pharma Ltd

Management

Register Office

Registrar Office

Managing Director

Umang Alkesh Gosalia

Non-Exec. & Independent Dir.

Ami R Shah

Non-Exec. & Independent Dir.

Nikhil S. Uchat

Company Sec. & Compli. Officer

Bhakti Rameshbhai Aghera

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Incorporated in Nov.94, Parmax Pharma Ltd (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara. The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmaxs pharmaceutical operations. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc. The Company then discontinued their business activities for few years due to various reasons. Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA. Antibiotic project was fully implemented from 31st May97.
Read More

Company FAQs

What is the Parmax Pharma Ltd share price today?

The Parmax Pharma Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹46 today.

What is the Market Cap of Parmax Pharma Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Parmax Pharma Ltd is ₹17.21 Cr. as of 09 May ‘25

What is the PE and PB ratio of Parmax Pharma Ltd?

The PE and PB ratios of Parmax Pharma Ltd is 0 and -21.65 as of 09 May ‘25

What is the 52 Week High and Low of Parmax Pharma Ltd?

The 52-week high/low is the highest and lowest price at which a Parmax Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Parmax Pharma Ltd is ₹25.03 and ₹55.02 as of 09 May ‘25

What is the CAGR of Parmax Pharma Ltd?

Parmax Pharma Ltd's CAGR for 5 Years at 16.00%, 3 Years at 8.32%, 1 Year at 60.38%, 6 Month at -3.34%, 3 Month at -2.42% and 1 Month at 4.77%.

What is the shareholding pattern of Parmax Pharma Ltd?

The shareholding pattern of Parmax Pharma Ltd is as follows:
Promoters - 30.80 %
Institutions - 0.00 %
Public - 69.20 %

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.